ClinConnect ClinConnect Logo
Search / Trial NCT06301607

The Impact of Oral and Nasal Enteral Nutrition Feeding Quantity in Stroke Patients

Launched by MUHAMMAD · Mar 4, 2024

Trial Information

Current as of August 20, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is designed to compare two different methods of providing nutrition to patients who have had an ischemic stroke, which is a type of stroke caused by a blockage in blood flow to the brain. The study will look at how much nutrition patients receive and their overall nutritional health using two types of feeding tubes: an Intermittent Oro-esophageal Tube and a Nasogastric Tube. Patients will be randomly assigned to one of the two groups, both of which will receive regular rehabilitation treatment. The researchers want to see if using the Oro-esophageal Tube leads to better nutrition and greater food intake compared to the Nasogastric Tube.

To participate in this trial, individuals need to be at least 18 years old and diagnosed with ischemic stroke. They must also have difficulty swallowing, confirmed by a special test, and be alert and stable. However, those with swallowing problems from other conditions or severe health issues, as well as pregnant or nursing women, will not be eligible. Participants can expect to have their nutritional intake and health monitored throughout the study to help determine the best feeding method for stroke recovery. The trial is not yet recruiting participants, so there will be additional information available when it begins.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age\>18 years.
  • Meeting the diagnostic criteria for ischemic stroke .
  • Dysphagia confirmed by Videofluoroscopic Swallowing Study.
  • Clear consciousness.
  • No history of prior stroke.
  • Stable vital signs.
  • Exclusion Criteria:
  • Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc.
  • Complicated with severe liver and kidney failure, tumors, or hematological disorders.
  • Simultaneously in need to undergo other therapy that might affect the outcomes of this study.
  • Pregnant or nursing females.

About Muhammad

Muhammad is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Muhammad collaborates with leading research institutions and healthcare professionals to design and implement rigorous clinical trials. The organization prioritizes ethical standards and patient safety while striving to accelerate the development of new treatments across various therapeutic areas. Through its commitment to scientific excellence and collaboration, Muhammad aims to contribute significantly to the evolving landscape of healthcare.

Locations

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Trial Officials

Nieto Luis, Master

Study Director

Site Coordinator of United Medical Group

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported